Geostrategies of the European neighbourhood policy

The debate about the European Neighbourhood Policy (ENP) has, in essence, been about borders and bordering. Such departures could contribute — and often do so — to a rather fixed geopolitical vision of what the EU is about and how it aims to run and to organize the broader European space. However, this article aims to retain space for viewing the ENP as a developmental and somewhat fluid process. A conceptual framework, based on outlining three geopolitical models and a series of different geopolitical strategies employed by the EU in regard to its borders, is hence employed in order to be able to tell a more dynamic story regarding the developing nature of the ENP and the EU's evolving nature more generally. The complexity traced informs us that various geostrategies may be held at the same time at the external border. Moreover, the dominance of one geostrategy may be replaced by another or a different combination of them with regard to the same neighbourhood. It is, more generally, argued that if anything it is precisely this dynamism that should be championed as a valuable resource, avoiding the tendency to close off options through the reification of particular visions of the nature of the EU and its borders

A novel antibody combination to identify KIR2DS2(high) NK cells in KIR2DL3/L2/S2 heterozygous donors

The killer cell immunoglobulin‐like receptor (KIR) KIR2DS2 induces NK cell activation upon ligation and in genetic studies is associated with protection against certain cancers and viral infections. One of the difficulties in understanding KIR2DS2 has been that ligands have been hard to define. In part, this is because the high sequence homology between KIR2DS2 and KIR2DL3/KIR2DL2 has made it difficult to make antibodies that specifically detect NK cells expressing KIR2DS2. Using transfected NKL cells and primary human samples, we report the identification of a novel antibody combination which allows identification of NK cells with relatively high expression of KIR2DS2. This separation is sufficient to examine primary human NK cell activation in response to KIR2DS2 specific ligands

Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma

Background: Hepatocellular carcinoma (HCC) is common, but remains difficult to treat. Natural killer (NK) cells are cells of the innate immune system that have potent anti-cancer activity. Recent work has shown that stimulation with IL-12/15/18 leads to the generation of NK cells with enhanced functional and putative �memory� properties. We have investigated the activity of these NK cells against HCC cell lines in vitro and in a mouse model. Methods: NK cells from healthy donors or individuals with HCC were activated with IL-12/15/18 in vitro and tested for cytotoxic activity against a panel of human HCC cell lines. IL-12/15/18 primed murine NK cells were then infused into a murine model of spontaneously arising HCC to test for anti-tumor activity. Results: NK cells from patients and healthy controls had similar expression levels of activating and inhibitory NK cell receptors. However, proliferation of NK cells from HCC patients was weaker than healthy controls in response to IL-12/15/18 and IL-2 (p &lt; 0.001 at day 9). In vitro, NK cells from both groups of individuals killed HCC targets to similar levels and this was unrelated to NKG2D expression. In a spontaneous model of HCC, IL-12/15/18 activated NK cells trafficked to the liver and resulted in lower levels of spontaneous HCC formation (p &lt; 0.01). Conclusion: Cytokine-primed NK cells from patients with HCC have similar levels of activity against HCC cell lines as those from healthy controls. This type of activated NK cell has immunotherapeutic potential against hepatocellular carcinoma.</p

A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors.

The killer cell immunoglobulin-like receptor (KIR) KIR2DS2 induces natural killer (NK) cell activation upon ligation and in genetic studies is associated with protection against certain cancers and viral infections. One of the difficulties in understanding KIR2DS2 has been that ligands have been hard to define. In part, this is because the high sequence homology between KIR2DS2 and KIR2DL3/KIR2DL2 has made it difficult to make antibodies that specifically detect NK cells expressing KIR2DS2. Using transfected NK cell line (NKL) cells and primary human samples, we report the identification of a novel antibody combination which allows identification of NK cells with relatively high expression of KIR2DS2. This separation is sufficient to examine primary human NK cell activation in response to KIR2DS2 specific ligands